Please login to the form below

Not currently logged in
Email:
Password:

FDA votes to keep severe warning on Pfizer’s Chantix

Will not relax anti-smoking drug's side effect warning

FDA headquarters White Oak

Pfizer has failed to convince the US Food and Drug Administration (FDA) to remove a black box warning on its quit-smoking drug Chantix.

An advisory panel to the agency voted against the removal this wee,k but agreed to revisit the issue once data from Pfizer's post-marketing study for Chantix (varenicline) is available. 

The firm is currently conducting a study on 8,000 people comparing Chantix with two other smoking-cessation treatments and a placebo in terms of possible serious neuropsychological effects. Data from the study is expected in the third quarter of 2015.

Steve Romano, senior vice president of Pfizer's global innovative pharmaceutical business, told Reuters: “I'm hoping the data confirms all the information we already have.”

The FDA placed a black box warning - its most severe and restrictive warning - on the product in 2009, highlighting the possibility of mental health issues found in patients using the drug, including depression and suicidal thoughts.

The National Centre for Health Research (NCHR) is one of five non-profit organisations that had filed a citizen petition asking the FDA to include risks of aggression, violence, psychosis and depression in the black box warning.

Diana Zuckerman, president of the NCHR, called the drug's side effects “distinctly worrisome”.

Analysts have said the retention of the warning label is not expected to have an impact of Pfizer's sales or profits. Chantix was Pfizer's 15th best selling drug of 2013.

Article by
Kirstie Pickering

20th October 2014

From: Regulatory

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
3 Monkeys Zeno

3 Monkeys Zeno is an award winning global creative communications consultancy – home to a collective of creative and strategic...

Latest intelligence

Article:
The disparity of patient experiences with Crohn’s Disease in Europe and Japan...
Patient diversity in clinical trials
The pursuit of patient diversity in clinical trials
When all-inclusive isn’t an option, it’s an obligation...
Overcoming the digital patient recruitment challenges of connecting with patients
How many irrelevant experiences, ads, emails, direct messages have you rejected this week?...